for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Seattle Genetics, Inc.

SGEN.OQ

Latest Trade

74.01USD

Change

1.23(+1.69%)

Volume

763,438

Today's Range

72.75

 - 

74.39

52 Week Range

50.73

 - 

84.35

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
72.78
Open
73.15
Volume
763,438
3M AVG Volume
20.51
Today's High
74.39
Today's Low
72.75
52 Week High
84.35
52 Week Low
50.73
Shares Out (MIL)
168.78
Market Cap (MIL)
12,292.30
Forward P/E
-55.52
Dividend (Yield %)
--

Next Event

Q3 2019 Seattle Genetics Inc Earnings Release

Latest Developments

More

Seattle Genetics And Astellas Announce U.S. FDA Grants Priority Review For Enfortumab Vedotin Biologics License Application In Locally Advanced Or Metastatic Urothelial Cancer

Seattle Genetics Announces Pricing Of Public Offering Of Common Stock

Seattle Genetics Announces Proposed Public Offering Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Seattle Genetics, Inc.

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). In addition to ADCETRIS, the Company's pipeline includes other clinical-stage ADC programs, such as ASG-22ME, SGN-LIV1A, SGN-CD19A, SGN-CD19B, SGN-CD123A, SGN-352A, and ASG-15ME, as well as two immuno-oncology agents, SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology, and SGN-2FF, which is a small molecule. It also has multiple preclinical and research-stage programs that employ its technologies, including SGN-CD48A and a preclinical ADC. ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent.

Industry

Biotechnology & Drugs

Contact Info

21823 30th Dr SE

+1.425.5274000

http://www.seattlegenetics.com/

Executive Leadership

Clay B. Siegall

Chairman of the Board, President, Chief Executive Officer

Todd E. Simpson

Chief Financial Officer

Jean I. Liu

Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary

Vaughn B Himes

Chief Technical Officer

Roger Dansey

Chief Medical Officer

Key Stats

2.18 mean rating - 17 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.4K

2017

0.5K

2018

0.7K

2019(E)

0.8K
EPS (USD)

2016

-1.000

2017

-0.880

2018

-1.410

2019(E)

-1.312
Price To Earnings (TTM)
--
Price To Sales (TTM)
16.23
Price To Book (MRQ)
9.26
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-20.38
Return on Equity (TTM)
-17.77

Latest News

Seattle Genetics, Astellas drug rapidly shrinks tumors in bladder cancer study

An experimental drug developed by Seattle Genetics Inc and Astellas Pharma Inc led to significant, rapid tumor shrinkage in patients with advanced bladder cancer who had been previously treated with immunotherapy and chemotherapy in a midstage trial, according to data presented...

CORRECTED-Seattle Genetics, Astellas drug shows rapid tumor shrinkage in advanced bladder cancer study

An experimental drug developed by Seattle Genetics Inc and Astellas Pharma Inc led to significant, rapid tumor shrinkage in patients with advanced bladder cancer who had been previously treated with immunotherapy and chemotherapy in a midstage trial, according to data presented...

BRIEF-Seattle Genetics Reports Q1 Loss Per Share Of $0.73

* SEATTLE GENETICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Seattle Genetics Says CEO Clay Siegall's 2017 Total Compensation Was $8.6 Mln Vs $9.6 Mln In 2016

* SEATTLE GENETICS INC SAYS CEO CLAY B. SIEGALL'S 2017 TOTAL COMPENSATION WAS $8.6 MLN VS $9.6 MLN IN 2016 – SEC FILING Source text: (https://bit.ly/2GxkWMO) Further company coverage:

BRIEF-Seattle Genetics And Astellas Receive FDA Breakthrough Therapy Designation For Enfortumab Vedotin

* SEATTLE GENETICS AND ASTELLAS RECEIVE FDA BREAKTHROUGH THERAPY DESIGNATION FOR ENFORTUMAB VEDOTIN IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER

Seattle Genetics' Hodgkin's lymphoma drug wins U.S. approval

U.S. regulators on Tuesday approved Seattle Genetics Inc's Adcetris as part of a chemotherapy cocktail to treat advanced Hodgkin's lymphoma in newly diagnosed patients, making it the first new treatment in over 40 years.

BRIEF-Seattle Genetics Announces FDA Approval Of Adcetris

* SEATTLE GENETICS ANNOUNCES FDA APPROVAL OF ADCETRIS® (BRENTUXIMAB VEDOTIN) IN COMBINATION WITH CHEMOTHERAPY FOR ADULTS WITH PREVIOUSLY UNTREATED STAGE III OR IV CLASSICAL HODGKIN LYMPHOMA

Seattle Genetics' Hodgkin's lymphoma drug gets U.S. approval

U.S. regulators on Tuesday approved Seattle Genetics Inc's Adcetris as part of a chemotherapy cocktail to treat advanced Hodgkin's lymphoma in newly diagnosed patients.

BRIEF-Unum Therapeutics Sees IPO Of 5.8 Mln Shares Priced $12 - $14 Per Share

* UNUM THERAPEUTICS INC SEES IPO OF 5.8 MILLION SHARES OF COMMON STOCK PRICED TO BE BETWEEN $12.00 AND $14.00 PER SHARE - SEC FILING

BRIEF-Seattle Genetics Appoints Alpna Seth To Board

* SEATTLE GENETICS APPOINTS DR. ALPNA SETH TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-Pharma Mar Licenses Marine-Derived Payloads To Seattle Genetics

* LICENSES FULLY SYNTHETIC MARINE-DERIVED PAYLOADS TO SEATTLE GENETICS FOR USE IN DRUG CONJUGATES

BRIEF-Seattle Genetics And Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration

* SEATTLE GENETICS AND PIERIS PHARMACEUTICALS ANNOUNCE MULTI-PROGRAM IMMUNO-ONCOLOGY COLLABORATION

BRIEF-Pieris Pharmaceuticals And Seattle Genetics Announce Multi-Program Immuno-Oncology Collaboration

* PIERIS PHARMACEUTICALS AND SEATTLE GENETICS ANNOUNCE MULTI-PROGRAM IMMUNO-ONCOLOGY COLLABORATION Source text for Eikon: Further company coverage:

BRIEF-Seattle Genetics Commences Tender Offer For Cascadian Therapeutics

* SEATTLE GENETICS COMMENCES TENDER OFFER FOR CASCADIAN THERAPEUTICS, INC.

BRIEF-Seattle Genetics Announces Full Exercise Of Underwriters’ Option To Purchase Additional Shares

* SEATTLE GENETICS ANNOUNCES FULL EXERCISE OF UNDERWRITERS’ OPTION TO PURCHASE ADDITIONAL SHARES Source text for Eikon: Further company coverage:

BRIEF-Seattle Genetics Says If Deal Terminated Under, Cascadian Therapeutics To Pay Fee Of $17 Million

* SEATTLE GENETICS SAYS IF DEAL TERMINATED UNDER CERTAIN CIRCUMSTANCES, CASCADIAN THERAPEUTICS MAY BE REQUIRED TO PAY CO FEE OF $17 MILLION - SEC FILING Source text: (http://bit.ly/2E2RNXK) Further company coverage:

BRIEF-Seattle Genetics Commences Underwritten Public Offering Of $550 Mln Of Shares

* SEATTLE GENETICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Seattle Genetics To Acquire Cascadian Therapeutics

* SEATTLE GENETICS TO ACQUIRE CASCADIAN THERAPEUTICS, ADDING LATE-STAGE BREAST CANCER PROGRAM TO ITS ONCOLOGY PIPELINE

BRIEF-SEATTLE GENETICS ANNOUNCES FDA APPROVAL OF ADCETRIS (BRENTUXIMAB VEDOTIN)

* SEATTLE GENETICS ANNOUNCES FDA APPROVAL OF ADCETRIS® (BRENTUXIMAB VEDOTIN) FOR PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA (PCALCL) AND CD30-EXPRESSING MYCOSIS FUNGOIDES (MF)

BRIEF-Seattle Genetics, Astellas initiate phase 1b trial for Enfortumab Vedotin

* Seattle Genetics and Astellas initiate phase 1B trial of Enfortumab Vedotin in combination with immune checkpoint inhibitor therapies in locally advanced or metastatic urothelial cancer

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up